Metagenomi Inc MGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MGX is a good fit for your portfolio.
News
-
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
-
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
-
Metagenomi to Present at Upcoming Scientific Meetings
-
Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%
Trading Information
- Previous Close Price
- $7.00
- Day Range
- $6.66–7.23
- 52-Week Range
- $5.50–12.74
- Bid/Ask
- $6.40 / $6.73
- Market Cap
- $250.64 Mil
- Volume/Avg
- 46,990 / 130,812
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.93
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 236
- Website
- https://www.metagenomi.co
Valuation
|
Metric
|
MGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.91 |
Price/Sales | 3.93 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MGX
|
|---|---|
Quick Ratio | 4.66 |
Current Ratio | 4.75 |
Interest Coverage | — |
Quick Ratio
MGX
Profitability
|
Metric
|
MGX
|
|---|---|
Return on Assets (Normalized) | −17.32% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −288.45% |
Return on Assets
MGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fvszclvsyw | Xfnpn | $586.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vcmvkphzr | Kccdbm | $115.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nnnfdcrp | Xphxjz | $108.2 Bil | |
MRNA
| Moderna Inc | Dblhcsbg | Bbd | $54.0 Bil | |
ARGX
| argenx SE ADR | Cwtwxmxk | Nqly | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Tsrxvcsty | Mhxp | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qdhygtrf | Jvnhfy | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ynxzrny | Rllzrkh | $14.6 Bil | |
INCY
| Incyte Corp | Tvgjpwks | Kymjpbf | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Skxwxfqdp | Cqxdtqr | $12.3 Bil |